Skip to main content

A 12-month, multi-center, open-label study to investigate the safety of pegpleranib (1.5 mg) in combination with anti-VEGF agents, ranibizumab (0.5 mg) or aflibercept (2 mg), in Japanese patients with neovascular age-related macular degeneration

Research Grant
Duke Scholars

Administered By

Ophthalmology

Awarded By

Novartis Pharma AG

Start Date

October 1, 2016

End Date

December 14, 2016
 

Administered By

Ophthalmology

Awarded By

Novartis Pharma AG

Start Date

October 1, 2016

End Date

December 14, 2016